白癜风面积评分指数的心理测量学特性与有意义变化阈值
本研究基于一项2期随机临床试验的二次分析及嵌入式定性访谈,评估T-VASI和F-VASI在非节段性白癜风患者中的概念效度和测量性能,并确定有意义变化阈值。结果显示两工具重测信度良好,与医生整体评估相关性中至强,T-VASI改善30%和F-VASI改善50%可反映有意义复色,低于临床试验传统使用的T-VASI 50和F-VASI 75。
要点
- T-VASI和F-VASI在非节段性白癜风中信度、效度、区分度和反应性良好。
- T-VASI改善30%和F-VASI改善50%为有意义复色阈值。
- 传统T-VASI 50和F-VASI 75可能为保守估计。
核心结论
- T-VASI和F-VASI可靠、有效、能区分临床不同组别且对非节段性白癜风患者有反应性。
- 有意义变化阈值低于临床试验传统使用的阈值,提示T-VASI 50和F-VASI 75为保守估计。
研究设计与样本
- 混合方法研究,包括一项2期多中心双盲剂量范围随机临床试验的二次分析和嵌入式定性访谈。
- 研究在加拿大、法国、日本和美国的35个中心开展。
- 二次分析纳入该试验的成年非节段性白癜风患者,基线T-VASI≥5且F-VASI≥0.5。
- 定性分析纳入14名参与者(平均年龄48.8岁,标准差12.2;女性9名[64%],男性5名[36%])。
主要发现
- 心理测量分析纳入164名参与者(平均年龄46岁,标准差未报告;女性103名[63%])。
- 在临床稳定白癜风患者中,基线至第4周T-VASI的组内相关系数为0.98,F-VASI为0.99,支持重测信度。
- 基线和第24周时,T-VASI与PhGVA-T相关性为中度至强(r=0.63-0.65),F-VASI与PhGVA-F相关性为中度至强(r=0.65-0.71)。
- 采用多重锚定法,T-VASI评分改善30%和F-VASI评分改善50%反映基线与第24周之间有意义的复色。
关键数值与推荐
- T-VASI重测信度组内相关系数0.98,F-VASI为0.99。
- T-VASI与PhGVA-T相关性r=0.63-0.65,F-VASI与PhGVA-F相关性r=0.65-0.71。
- 有意义复色阈值:T-VASI改善30%,F-VASI改善50%。
临床怎么用
- 临床解读非节段性白癜风治疗试验时,可参考T-VASI改善30%和F-VASI改善50%作为有意义复色阈值。
- 传统T-VASI 50和F-VASI 75阈值可能高估了患者所需的有意义改善程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Defining meaningful improvement using the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) aids interpretation of findings from clinical trials evaluating vitiligo treatments; however, clear and clinically meaningful thresholds have not yet been established. OBJECTIVE: To assess concept validity and measurement performance of the T-VASI and F-VASI in patients with nonsegmental vitiligo and to identify meaningful change thresholds. DESIGN, SETTINGS, AND PARTICIPANTS: This mixed-methods study consisted of a secondary analysis of a phase 2 multicenter double-blind dose-ranging randomized clinical trial and embedded qualitative interviews conducted at 35 sites in Canada, France, Japan, and the US. The secondary analysis included the trial's adult patients with nonsegmental vitiligo (T-VASI ≥5 and F-VASI ≥0.5 at baseline). Psychometric performance of the T-VASI and F-VASI and thresholds for meaningful change were evaluated using clinician- and patient-reported information. The trial's embedded interviews were used to qualitatively assess content validity and patient perceptions of meaningful repigmentation. Data analyses were performed from March to July 2023. INTERVENTION: Participants were randomized to 6-, 11-, or 22-mg/day upadacitinib or placebo for 24 weeks. MAIN OUTCOMES AND MEASURES: Psychometric performance of the T-VASI and F-VASI and thresholds for meaningful changed plus content validity and patient perceptions of meaningful repigmentation. Measurement instruments included the T-VASI, F-VASI, Vitiligo Noticeability Scale, Total-Patient Global Vitiligo Assessment, Face-Patient Global Vitiligo Assessment, Total-Physician Global Vitiligo Assessment (PhGVA-T), Face-Physician Global Vitiligo Assessment (PhGVA-F), Patient's Global Impression of Change-Vitiligo, Physician's Global Impression of Change-Vitiligo (PhGIC-V), Vitiligo Quality-of-Life Instrument, Dermatology Life Quality Index, the Hospital Anxiety and Depression Scale, and transcribed verbatim interviews with patients. RESULTS: The psychometric analysis included 164 participants (mean [SD] age, 46 years; 103 [63%] females) and the qualitative analysis included 14 participants (mean [SD] age, 48.8 [12.2] years; 9 females [64%] and 5 males [36%]). Intraclass correlation coefficients were 0.98 for T-VASI and 0.99 for F-VASI in patients with clinically stable vitiligo between baseline and week 4, supporting test-retest reliability. At baseline and week 24, correlations were moderate to strong between T-VASI and PhGVA-T (r = 0.63-0.65) and between F-VASI and PhGVA-F (r = 0.65-0.71). Average baseline and week-24 VASI scores decreased with repigmentation (ie, increasing PhGVA scores). Least-square mean VASI scores increased with greater repigmentation as measured by the PhGIC-V. Least-square mean VASI scores also differed between patients with improved PhGIC-V and those with no change or worsened V-PhGIC scores. Using a multiple anchor approach, improvements of 30% in T-VASI and 50% in F-VASI scores reflected meaningful repigmentation between baseline and week 24. CONCLUSION AND RELEVANCE: This mixed-methods study found that the T-VASI and F-VASI are reliable, valid, able to differentiate between clinically distinct groups, and responsive in patients with nonsegmental vitiligo. The thresholds for meaningful change were lower than those historically used in clinical trials, suggesting that T-VASI 50 and F-VASI 75 are conservative estimates and reflect improvements that would be meaningful in patients with nonsegmental vitiligo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04927975.
引用
- Ezzedine K, Soliman AM, Camp HS, et al. Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index. JAMA Dermatol. 2025. PMID: 39475960. doi:10.1001/jamadermatol.2024.4534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。